Edith Zemanick
Overview
Explore the profile of Edith Zemanick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wood C, Moheet A, Vigers T, Granados A, Lorenz A, Hanley E, et al.
J Cyst Fibros
. 2025 Mar;
PMID: 40089409
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been highly effective for improving pulmonary disease and nutritional outcomes. However, the effect of this therapy on glycemic control in people with cystic fibrosis related diabetes...
2.
Zemanick E, Burgel P, Taccetti G, Holmes A, Ratjen F, Byrnes C, et al.
J Cyst Fibros
. 2019 Nov;
19(3):370-375.
PMID: 31680041
Background: Antimicrobial susceptibility testing (AST) is a cornerstone of infection management in cystic fibrosis. However, there is little evidence that AST predicts the clinical outcome of CF antimicrobial treatment. It...
3.
Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel S, et al.
J Cyst Fibros
. 2018 Aug;
18(1):144-149.
PMID: 30104123
Background: The effects of lumacaftor-ivacaftor therapy on glycemia have not been thoroughly investigated. Continuous glucose monitoring (CGM) provides detailed information about glycemic patterns and detects glucose abnormalities earlier than traditional...
4.
Flass T, Tong S, Frank D, Wagner B, Robertson C, Kotter C, et al.
PLoS One
. 2015 Feb;
10(2):e0116967.
PMID: 25658710
Background And Aims: Cirrhosis (CIR) occurs in 5-7% of cystic fibrosis (CF) patients. We hypothesized that alterations in intestinal function in CF contribute to the development of CIR. Aims: Determine...